Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.83) by 4.82 percent. This is a 11.24 percent increase over losses of $(0.89) per share from the same period last year.
Related Posts
Reported Late Tuesday Feb. 28, Hillman Announces Upsize And Pricing Of Secondary Offering Of 25M Shares Of Common Stock At A Price Of $8/Share By Selling Stockholders
Hillman Solutions Corp. (Nasdaq: HLMN) (the "Company" or "Hillman"), a leading provider of hardware products and merchandising solutions, today announced the upsize and pricing of
Horizon Space Acquisition I Prices $60M Initial Public Offering At $10/Unit
Horizon Space Acquisition I Corp. (the "Company"), a newly organized blank check company incorporated as a Cayman Islands exempted company and led by Chairman and CEO Mingyu (Michael) Li,
Stifel Maintains Buy on Rocket Lab USA, Lowers Price Target to $15
Stifel analyst Erik Rasmussen maintains Rocket Lab USA (NASDAQ:RKLB) with a Buy and lowers the price target from $18 to $15.